A groundbreaking study has found that an experimental drug can reverse liver cell aging in rats, reducing levels of a protein associated with Alzheimer's disease by half and lowering bad cholesterol to youthful levels. The research, conducted by scientists at the Keck School of Medicine of USC, suggests that targeting the liver could be a new approach to preventing age-related illnesses. The study focused on liver sinusoidal endothelial cells (LSECs), which form the lining of tiny blood vessels inside the liver and play a crucial role in filtering the blood and removing unwanted compounds. As the liver ages, the openings in LSECs gradually become smaller or disappear, making it harder for certain large molecules to reach the cells responsible for clearing them. The researchers administered an experimental drug called cinaciguat to aged rats and found that it restored the structure and function of the aging LSECs, reopening their microscopic pores and improving their ability to help clear substances from the blood. The treatment also reduced levels of amyloid beta, a protein associated with Alzheimer's disease, by approximately 50% and lowered LDL, or bad cholesterol, to levels comparable to those in young rats. The study also uncovered a previously unknown sequence of biochemical signals that helps coordinate the liver's ability to remove substances from the bloodstream. The researchers found that cinaciguat activates an enzyme called soluble guanylate cyclase inside LSECs, which triggers the release of a growth factor known as HB-EGF. This signal is then sent to nearby hepatocytes, which alter their surfaces to capture more LDL and amyloid beta from the blood. The discovery identifies a potential new target for future drugs, which could restore the chemical signals responsible for helping the liver work efficiently. While the study has only been conducted in rats, the findings raise the possibility that liver rejuvenation could be a new approach to preventing Alzheimer's and cardiovascular problems. However, further research is needed to determine whether the effects of cinaciguat translate into meaningful protection against disease.